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Type 2 Diabetes Mellitus (T2DM) is characterized by chronic hyperglycemia with disturbance in carbohydrate, lipid, and protein
metabolism due to insulin resistance and beta cell dysfunction. Epidemiological studies have conﬁrmed a global pandemic of
T2DM, which has created an enormous burden on society, with regard to morbidity, mortality, and health care expenditures.
Life style modiﬁcations are fundamental not only in early stages of disease management but need to be intensiﬁed as disease
progresses. United Kingdom Prospective Diabetes Study (UKPDS) has demonstrated the progressive nature of T2DM, and as
disease progresses, a combination agents—oral antidiabetic drugs (OAD) and insulin—are needed in order to maintain good
sugarcontrol. Thegeneral consensusofHbA1ctarget formostpatients islessthan 7%,and variousguidelines and algorithmshave
provided guidance in patient management to keep patient at goal. As our understanding of pathophysiological defects advances,
targeting treatment at underlying defects not only enables us to achieve HbA1c goal but also reduces morbidities, mortalities, and
progression of the disease. Traditional oral agents like metformin and sulfonylureas have failed to arrest the progression of T2DM.
New agents such as TZD, DPP-4 inhibitor, and SGLT-2 may increase our armamentariums against T2DM.
1.Pathophysiology ofT2DM
Both genetic and environmental factors play an important
role in the pathogenesis of T2DM. The best studied patho-
physiological defects in T2DM are insulin resistance and
insulin secretary dysfunction of β-cell [1]. The former is
primarily represented by decreased insulin-stimulated glu-
cose uptake in skeletal muscle, unsuppressed hepatic glucose
production, and increased lipolytic activity in adipose tissue.
T h el a t t e ri sa na p p a r e n tp r o g r e s s i v ep r o c e s sw i t hb o t hf u n c -
tional defects in islet cell function and, eventually, apparent
loss of β- c e l lm a s s[ 2]. In Pima, Indian insulin resistance
proceeds beta cell dysfunction while in others beta-cell
dysfunction starts early in the natural history of disease pro-
gression [3]. The diﬀerence probably related to genetic fac-
tors.Recentstudiesalsofoundthatadysfunctionofglucagon
secretion and impaired incretin system contribute to hyper-
glycemia in T2DM, which will provide untapped potential
for the betterment of diabetes care [4–6].
2. CurrentOral AntidiabeticDrugs(OADs)
Currently six classes of OADs are available, and a new one is
around the corner. They can be classiﬁed into insulin secret-
agogue (sulfonylureas, meglitinides), insulin sensitizer (thi-
azolidinediones), decrease glucose ﬂux (alpha-glucosidase
inhibitors), incretin mimetic agent (DPP-4 inhibitor), and
glycosuric agent (Table 1). An important message from the
table is that not a single agent is eﬀective in tackling all the
pathophysiological defects of T2DM.
2.1. Sulfonylurea (SU). SUs have played an important role
in hyperglycemia management because of their potency, fast
action, and relative low cost. The United Kingdom Prospec-
tive Diabetes Study (UKPDS) results conﬁrmed that ﬁrst-
line therapy with sulfonylureas in newly diagnosed T2DM
is a safe and eﬀective treatment for glucose control [7].
SUs work by stimulating insulin secretion; although there
is evidence of extra pancreatic eﬀect, the clinical eﬀect is2 ISRN Endocrinology
Table 1: Diﬀerent classes of oral antidiabetic agents (OAD) and clinical indications.
α Glucosidase
Inhibitors Meglitinides SUs TZDs Metformin DPP-4
Inhibitors SGLT-2
Insulin deﬁciency     
Insulin resistance   
Excess hepatic glucose output    
Intestinal glucose absorption   
Glycosuria  
Amori et al. [41];
Abdul-Ghani et al. [47];
DeFronzo [17].
probably insigniﬁcant [8]. The ﬁrst-generation agents (ace-
tohexamide, chlorpropamide, tolazamide, and tolbutamide)
have a lower binding aﬃnity to the receptor on the β-cells, so
they must be given in higher doses than the second genera-
tion agents, (glimepiride, glipizide, gliclazide, and glyburide)
which have a higher binding aﬃnity. Among the second
generation agents, there are diﬀerence in their diﬀerential
binding speciﬁcity to beta-cell SUR1 and SUR-2 in cardiac
muscle [9]. All the SUs act by binding to the SUR-1 subunit
of KATP channels, causing them to close and increase intra-
cellularpotassium,whichtriggersmembranedepolarization.
Membrane depolarization opens up calcium channel and
causes inﬂux of calcium. Increase in intracellular calcium
stimulates migration and exocytosis of insulin granules [10].
Diﬀerences in insulin secretory characteristics of the various
insulin secretagogues depend on their pharmacokinetic and
the aﬃnity and kinetics of their binding to SUR-1 subunit.
They have comparable eﬃcacy as illustrated in Table 2.
T h ec o m m o ns i d ee ﬀects are hypoglycemia, weight gain,
and secondary failure [11]. Secondarily SU failure rate is
r e p o r t e dt ob ea r o u n d5t o1 0p e r c e n to fp a t i e n t sp e ry e a r
[12]. Secondary failure can have many causes including
progression of the disease, stress, infection, introduction of
other drugs, for example, corticosteroids, noncompliance, or
nonadherence to diet and exercise. Most of the hypoglycemic
eﬀects of the sulfonylureas will be observed at one half of the
maximum dose recommended for a speciﬁc agent [13].
Ever since tolbutamide was implicated with increased
mortality secondary to cardiovascular events in the Uni-
versity Group Diabetes Program (UGDP) study, debate on
SU cardiovascular safety continues [14]. Recent population
studies [15, 16] reported increased coronary heart event
and mortality with increased dose of SU exposure, and
plausible mechanisms have been related to blockage of SUR-
2 receptor in myocardium and impaired the preischemic
precondition of myocardium [17]. While the cardiovascular
adverse eﬀects associated with SUs remain controversial, it
would be rational to dose SUs at the lowest therapeutically
eﬀective dose, thus avoiding the loss of selectivity of these
agents for pancreatic KATP channels. Sulfonylureas should
be started at low doses and titrated up every 1 to 4 week.
A linear dose-response relationship does not exist through-
out the manufacturers’ dose range for SUs [18]. In patients
who are not responding at one half of the maximum dose,
an alternative agent or combination therapy should be con-
sidered. Combining a drug that increases insulin secretion
with one that improves insulin action is therapeutically
worthwhile.
2.2. Nonsulfonylurea Insulin Secretagogue
2.2.1. Repaglinide/Nateglinide. Nonsulfonylurea insulin sec-
retagogue has a mechanism of action that is similar to SU.
They bind to kir-6.2 subunit of SU receptor of β-cell [10].
Characteristicsofthesegroupofagentsincludearapidaction
and short duration of action. The ability to titrate time and
dose of the medication to match meal ingestion time greatly
decreases in postprandial sugar surge and decreases risk of
hypoglycemia. They are good for patients with an irregular
meal pattern as they allow greater ﬂexibility for the patient
in terms of meal time and dose adjustment. It is to be taken
within 30 minutes of each meal with an extra tablet for extra
meal and skip a tablet if a meal is skipped. Nonsulfonylurea
insulin secretagogues are metabolized by the liver, and
although there are no contraindications for patient with
renal impairment, the dose should be reduced in cases of
impaired liver disease. In general, eﬃcacy is comparable
to other SUs with repaganides but less with nateglinides
(Tables2and3).SideeﬀectsaresimilartoSUsbutlessweight
gain. Hypoglycemia is uncommon and is usually mild. In
the most recent diabetes prevention trial, “The nataglinides
and valsartan in impaired glucose tolerance outcome research
(navigator) study”, Nateglinide have not been proved to have
a beneﬁt on any cardiovascular outcome [19].
2.3. Thiazolidinediones. Pioglitazone belongs to the class of
thiazolidinediones and is an activator of the nuclear tran-
scription factor, peroxisome proliferator-activated receptor-
γ (PPAR-γ), which modulates the activity of a host of genes
that regulate carbohydrate and lipid metabolism. Its major
actions are to increase insulin-mediated glucose uptake
(improves insulin sensitivity) in muscles, increases adipo-
genesis, preserves beta cell function, and modulates hepatic
gluconeogenesis. The ﬁrst-generation thiazolidinediones,
troglitazone, were withdrawn from the market because of
hepatotoxicity and the second-generation, rosiglitazone, is
the only in restricted market because of suspected cardiac
side-eﬀect. Pioglitazone is the only drug of the class stillISRN Endocrinology 3
Table 2: Mechanism, site of action, and eﬃcacy for oral Antidiabetic agents and CHD beneﬁt.
Drug class Mechanism of action Primary site of
action
Reduction in
FBS
Reduction in
HbA1c CHD beneﬁt
Sulfonylureas∴ Insulin release Pancreas 3.34–3.88 1.0–2.0 −
Nonsulfonylurea
secretagogues Insulin release Pancreas 3.34–3.88 0.07–2.0 −
Biguanides
Hepatic glucose production; insulin
sensitivity in hepatic and peripheral
tissues
Liver; peripheral
tissues 3.34–3.88 1.0–2.0 +
Thiazolidinediones Insulin sensitivity in peripheral tissues;
hepatic glucose production
Peripheral
tissues; liver 1.90–2.22 0.7–1.0 +
Alpha-glucosidase
inhibitors Delay carbohydrate absorption Small intestines 1.38–1.66 0.5–1.0 +
DDPIV inhibitors∗ Enhance endogenous GLP-1 β-cell, stomach,
liver 0.5–1.0 0.73–1.2 +/−
SGLT-2# Inhibitor of renal proximal tubular
reabsorption
Renal tubular
SGLT-2 receptor 0.6–1.2 0.37–0.72 +/−
DeFronzo [17]; Nathan [66].
#Bailey et al. [45]. ∗Amori et al. [41].
widely available. It has moderate eﬃcacy in lowering fasting
blood sugar and HbA1c [20]. It has a favorable eﬀect on lipid
proﬁle, decreases plasma triglyceride, and increases high-
density lipoprotein [10]. In PRO-ACTIVE study, pioglita-
zone has shown to reduce composite of all-cause mortality,
nonfatal myocardial infarction, and stroke in people with
T2DM who have a high risk of macrovascular events [21].
Studies with thiazolidinediones in prediabetes, impaired
glucose tolerance (IGT), impaired fasting glucose (IFG), had
demonstrated signiﬁcant reduction in progression from IGT
to T2DM by 62–72% [22–24]. It is more eﬀective in obese
subjectsand should be used early in the treatment of patients
with T2DM to delay disease progression and to minimize the
development of complications [25].
Hypoglycemia caused by pioglitazone is usually mild
unless in combination with SU and most common side-
eﬀect is ﬂuid retention. Though the incidence of congestive
heart failure in pioglitazone treated patients is very low, the
risk increases from 1% to 4-5% in patients already treated
with high dose insulin and pioglitazone [26]. A patient with
advance heart failure, New York Heart Association stage
III/IV, is a contraindication for pioglitazone. Retrospective
analysis of rosiglitazone and pioglitazone data pool revealed
that diabetes using thiazolidinediones had a higher risk of
distal upper and lower limb fractures compared with those
not using thiazolidinediones. Fracture proportions were
higher among women and increased with age. The observed
excess risk of fractures for women in the pharmaceutical
company data set on pioglitazone is 0.8 fractures per 100
patient-years of use [27]. The risk of bladder cancer from
recent epidemiological data had prompted France and
Germany to suspend pioglitazone in early 2011. In July 2011,
the European Medicines Agency’s Committee for Medicinal
Products for Human Use (CHMP) conﬁrmed that Pioglita-
zone remains a valid treatment option for certain patients
with type 2 diabetes but acknowledges that there is a small
increased risk of bladder cancer in patients taking these
medicines and warns not to use these medicines in patients
withcurrentorahistoryofbladdercancerorinpatientswith
uninvestigated macroscopic haematuria [28].
2.4. Biguanide (Metformin). The major target of metformin
is the enzyme AMP-activated protein kinase (AMP-kinase).
Activation of AMP-kinase by metformin results in decrease
of hepatic glucose production and increase glucose transport
in skeletal muscle [29]. The overall eﬀect is a decrease
in hepatic gluconeogenesis due to improvement in hepatic
insulin sensitivity. Its insulin sensitizing eﬀect on peripheral
tissue has been minimal only. Its eﬃcacy in glucose control
had been well documented in UKPDS. Metformin use in the
newly diagnosed T2DM achieved comparable HbA1c lower-
ing to SU but without weight gain. Use in obese subgroup in
UKPDS was associated with improvement in cardiovascular
outcome. The risk of myocardial infarction was reduced by
39% and the overall diabetes-related mortality by 42% [30].
Most frequent side-eﬀects are related to the gastrointesti-
nal, tract, namely, nausea, poor appetite, abdominal discom-
fort, and diarrhoea. Long-term use has also been associated
with vitamin B12 deﬁciency [31, 32]. While the most feared
lactic acidosis (LA) is actually quite rare and mostly occurred
inclinicalsituationswheremetforminuseiscontraindicated,
the reported incidence of lactate acidosis in patients with
metformin is 3 per 100,000 patient years and a recent Co-
chrane review suggested there is no evidence that metformin
is associated with an increased risk for lactic acidosis when
prescribed under the study conditions [33]. The great major-
ity of cases of metformin-associated LA occur in connec-
tion with acute illness in diabetic patients where cardiac,
hepatic,pulmonary,orrenalfunctioniscompromised.There
are always at least two predisposing factors present in these
instances. It is, therefore, reasonable to assume that met-
formin is just a “bystander” [34].
Metformin is recommended by many algorithm/guide-
lines as the ﬁrst-line treatment and can be combined with4 ISRN Endocrinology
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otheroralhypoglycaemicagentswithcomplementaryaction.
In order to increase patient’s tolerance, it should be started
withalowdoseandincreasegraduallyoverweeks.Maximum
dose is 2500mg per day [35]. It is claimed that sustained
preparation is associated with better patient compliance and
better HbA1c improvement [36]. The drug should be used
with caution in elderly and patients with liver or renal
impairment. It is contra-indicated in chronic alcoholism and
creatine clearance less than 50mL/min. It should be stopped
for two days before contrast studies [36].
2.5. α-Glucosidase Inhibitor (Miglitol and Acarbose). The
mechanisms of all the α-glucosidase inhibitors are similar, as
a competitive inhibitor to the oligosaccharides for the bind-
ing site of α-glucosidase. They must be given at the start of
each meal. They must be started with a low dose and titrate
gradually within weeks. They mainly reduce postprandial
hyperglycaemia. The mean reduction in diet control T2DM
is about 3.0mmole/L and HbA1c 0.9% [37]. The most fre-
quent side-eﬀects of acarbose treatment are ﬂatulence and
diarrhoea. They can be used with T1DM orT2DM. In STOP-
NIDDM trial, acarbose not only prevented new diabetes
mellitus development but also suggested a reduction in
hypertension and cardiovascular disease [38].
2.6. Dipeptidyl Peptidase 4 (DPP-4) Inhibitors. People with
T2DM are known to have deﬁcient meal-related incretin
responses [4, 5], resulting in decreased insulin secretion,
increased postprandial glucagon levels, and elevated post-
prandial glucose [39]. This has led to the development of
a new class of drug call incretinmimetics, which are GLP-
1 analogue or GLP-1 receptor agonist and DPP4 inhibitors.
The former can only be given by injection while the latter are
orally active [40].
The highly selective DPP-4 inhibitors, sitagliptin,
saxagliptin, vildagliptin, and linagliptin, prevent normal
rapid degradation of endogenous glucagon-like-peptide-1
(GLP-1). They are selective because they inhibit DPP-4 sig-
niﬁcantly more than the related enzymes, DPP-8, and DPP-
9. GLP-1 and glucose-dependent insulinotropic polypeptide
(GIP) half-lives and protein levels are dramatically increased
when DPP-4 inhibitors are administered. These drugs reduce
postprandial and fasting glucose concentrations with sus-
tained decrease in HbA1c (0.7–1.3%) without weight gain
or signiﬁcant hypoglycemia [41]. They potentially preserve
β cell function with chronic use and have favorable safety
proﬁles. Neither weight loss nor nausea occurs with DPP-4
inhibitors.Themostcommonlyreportedadverseeventshave
been mild infections such as nasopharyngitis, upper respi-
ratory tract infection, and headaches. No clinically relevant
changes in laboratory immunologic parameters have been
found in studies of DPP-4 inhibitors, and pancreatitis was
reported at lower rates with the DPP-4 inhibitors compared
with other oral antidiabetic agents [42].
2.7. SGLT-2 Inhibitor: Dapagliﬂozin. A new approach in
management of hyperglycemia, as inspired by the congenital
familial renal glycosuria [43], is by inhibiting renal glu-
cose reabsorption. SGLT-2 is speciﬁc glucose transporter
in the proximal renal tubules. SGLT-2 inhibitors, such as
dapagliﬂozin, have been in clinical trials to prove clinical
application of these agents [44]. Use of SGLT-2 inhibitor
results in glycosuria in the order of 30–80gm/day, eliminat-
ing glucose from the circulation and the equivalent energy.
Recent data suggest that it has a moderate HbA1c lowering
eﬀect 0.5–0.8% [45]. Dapagliﬂozin has demonstrated eﬃ-
cacy, alone or in combination with metformin, in reducing
hyperglycemia in people withT2DM [44, 46].
It is metabolized by the liver and can be used in patients
with renal problem. Their mechanism of action is indepen-
dent of beta cell or insulin resistance. They can be added to
other oral antidiabetic drugs. Potential problems with SGLT-
2 inhibitor are risk of urinary tract infection and diuretic
eﬀect of glycosuria. Additional clinical studies are needed to
prove their safety and long-term eﬀectin natural progression
of T2DM and cardiovascular complication development
[47].
3 .T r ea tm e n tT a rg eta n d
Guidelines/Algorithm
Ingeneral,HbA1c<7%isthecommonlyacceptedtarget,but
in selected population, HbA1c < 6% is suggested [48, 49].
A lower or near normal HbA1c may be a good target for
younger patients with a shorter duration of T2DM and those
with no history of cardiovascular disease when one hopes to
prevent coronary heart disease [50].
Diﬀerent associations, ADA/EASD, AACE/ACE, NICE,
have published diﬀerent guidelines in diabetes management
[51–53]. Most of these adopt a stepwise approach with life
style modiﬁcations, exercise, and medical nutrition therapy,
as the ﬁrst step, followed by metformin and other oral hypo-
glycemic agents or insulin in subsequent steps. They diﬀer
in the second-line agents recommended, and this has caused
confusion among practitioners with diﬀerent cultural, soci-
etal, and economic development.
Insteadofaconventionalstepwiseapproach,theDeFron-
zo algorithm recommends metformin, pioglitazone, and ex-
enatide (GLP-1 agonist) as initial comprehensive treatment
[54]. The triple therapy will work complementary to each
other with the advantage of low risk of hypoglycemia, no
weight gain, and potential coronary heart disease risk pro-
tection, and prevention of beta cell function deterioration.
Deﬁnite proof of the therapy will come after completion of
the study, which is funded by ADA recently.
4. Strategy
A uniform treatment protocol is impossible for all regions
and no one protocol ﬁts all patients. After life style modiﬁ-
cations, pharmaceutical treatment usually starts with mono-
therapy, unless the patient is very symptomatic. If adequate
blood glucose control is not attained using a single oral agent
after 3–6 months, a combination of agents with diﬀerent
mechanisms of action may have additive therapeutic eﬀects
and result in better glucose control. Further deterioration
is to be expected with time, and insulin in various combi-
nations will be required ultimately if tight control of blood6 ISRN Endocrinology
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Figure 1: Algorithm in management of T2DM. NICE guidelines, May issue 2009 [53], Nathan et al. [51], Rodbard et al. [49], and Inzucchi
and McGuire [65].
sugar is required. Potential combinations are illustrated in
Figure 1. In practice, management of people with T2DM will
depend on consideration of at least four diﬀerent factors;
patient, disease, drug, and physician as depicted in Figure 2.
4.1. Disease. Treatment strategy is to address the pathophys-
iological defects and aims at correcting one or more of these
physiologicabnormalities,thatis,insulinresistance,beta-cell
dysfunction, and increased hepatic glucose output, and not
simply on the reduction in HbA1c. This will imply use of
diﬀerent drugs or combination of drugs at diﬀerent stages
of the disease. Treatment must be started early in the natural
historyofT2DMif β-cellfailureistobepreventedbecauseof
the “Metabolic legacy” as demonstrated by UKPDS [1, 55].
4.2. Drug: Potency and Safety the New and Old Agents.
Metformin and SU have served us well over half century and
they are still recommended by various algorithms. However,
they failed to sustain glucose control as a result of β-cell
failure as demonstrated by UKPDS [56]. Hypoglycemia is a
major and potential lethal side eﬀect with SUs, especially in
elderly and patient with cardiovascular disease (CHD). This
can be minimized by dosing at less than the manufacturers’
maximal recommended dose and avoiding high risk patients
and agent [14–18]. New agents such as pioglitazone and
DPP-4 inhibitors may oﬀer less hypoglycemia, potential
β-cell protection, sustain glycaemic control, and possibly
CHD protection in high risk patients. But pioglitazone is
associated with signiﬁcant distal fracture, heart failure, and
potential risk of bladder cancer. Though initial clinical data
Patient factor:
Age
Comorbidity
Preference
Genetic
Social/culture 
Disease factor: 
Pathophysiological defect
Stage of disease
Duration of illness
Drug factor:
Efﬁcacy
Safety
Cost 
Physician factor:
Clinical capacity
Judgment
Figure 2: Interaction between diﬀerent factors in choosing an
appropriate agent for T2DM management.
are promising, there are still no long-term safety data about
incretin-based treatment.
4.3. Patient. Diﬀerent patients may need diﬀerent regimens.
Genetic and cultural background diﬀerence may aﬀect their
response and adherence to speciﬁc drugs. The comorbid
states, such as coronary heart disease and kidney disease,
may pose them at particular risk such as heart failure, lactate
acidosis, hypoglycemia, and even fatal myocardial events.
As we learnt from ACCORD and ADVANCE studies thatISRN Endocrinology 7
patients with long duration disease or established coronary
disease should not have aggressive lowering of blood sugar
[57, 58].
4.4.Physician. Despitemanagementguidelinesrecommend-
ing increasingly tight targets for glycaemia control, a sig-
niﬁcant proportion of patients with type 2 diabetes do not
a c h i e v et a r g e tl e v e l so fg l y c a e m i ac o n t r o l .An u m b e ro fs t u d -
ies have shown that when targets are lower, a smaller propor-
tion of patients reach target; in China (CODIC-2), 68% had
HbA1c < 7.5% [59], Canada, 51% had HbA1c ≤ 7% [60],
and USA, only 37% HbA1c had <7% [61]. Europe had 31%
HbA1c < 6.5% [62]. In a cross-sectional survey of 24317
patients with diabetes mellitus among ﬁve diﬀerent Asia
countries, the majority (55%) had values exceeding 8%, in-
dicative of poor glycogenic control [63]. There appeared still
a gap between what is known and what is being done.
Study also found that because of clinical inertia, patients
accumulate several years of hyperglycemia before therapy is
intensiﬁed or changed. Encourage to change to an alternative
agent or early combination therapy when most of the hypo-
glycemic eﬀects are not observed at one half the maximum
dose of the sulfonylureas should be the ﬁrst step to reduce
time of exposure to chronic hyperglycemia and possible
complication [13, 64]. The decision to use speciﬁc agent
depends on judgment of physician after balancing all the
above factors.
5. Conclusion
Conventionally, drug interventions for T2DM have focused
on improvements of HbA1c, which proved to be important
in prevention of microvascular complication and cardiovas-
cular beneﬁt in long term. However, their eﬃcacy tends to
fail as disease progresses. New agents targeting at insulin
resistance and β-cell protection oﬀer eﬀective regimens to
slow disease progression and complication development.
Algorithm and guidelines may oﬀer suggestions in choosing
appropriate agents for general patient only. Each patient
diﬀerswithhisparticularsandhowtochoosetheappropriate
agent depends on each practitioner’s clinical judgment after
taking into consideration the risks and beneﬁts of each agent
and unique clinical features of each patient and stages of the
disease. Data are gathering to enable us to consider agent or
combination of agents to help arrest progression of T2DM
and prevent complication.
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